NCT04068272View on ClinicalTrials.gov

Safety of Bosentan in Type II Diabetic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 7, 2019

Primary Completion Date

May 20, 2022

Study Completion Date

May 20, 2022

Conditions
Diabetes Mellitus
Interventions
DRUG

Bosentan

Eyedrop

DRUG

Placebo

Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound

Trial Locations (2)

47011

IOBA, Valladolid

08907

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

OTHER

lead

Retinset SL

INDUSTRY

NCT04068272 - Safety of Bosentan in Type II Diabetic Patients | Biotech Hunter | Biotech Hunter